Elanco has announced a major boost to its U.S. operations with a $400 million investment in its Indiana facilities, strengthening both research and development capabilities and domestic manufacturing capacity. The expansion will support operations at the company’s new global headquarters in Indianapolis while reinforcing its U.S.-based production footprint.
As part of this momentum, the USDA has granted an accelerated pathway for conditional approval of a novel immuno-therapeutic, described as having “the potential to be a first-in-class major pet health blockbuster, expected in the next 2-3 years.” This milestone underscores the growing emphasis on bringing innovative animal health products to market more quickly.
Elanco credited recent federal policy as a driving factor behind its decision to deepen its U.S. investment strategy. According to the company, “The combination of a favorable tax environment from the One Big Beautiful Bill Act, regulatory reform resulting in improved timelines for USDA regulatory reviews and greater certainty on tariffs has created favorable conditions for the continuation of U.S. investments in R&D and manufacturing, while bringing key innovation capabilities from Europe to the U.S.”
U.S. Secretary of Agriculture Brooke Rollins celebrated the announcement publicly, highlighting its significance for both agriculture and American manufacturing. In a post on X, she stated, “The Golden Age of Agriculture is coming to the USA! Great to see Elanco investing $400m in Indiana! Two key factors outlined in their decision to relocate R&D facilities from the EU (which is bogged down by bureaucracy): Accelerating regulatory review timelines at USDA and America First trade policy that supports American manufacturing. President Trump has delivered trillions in new investments into the USA and is bolstering food security for Americans.”
Elanco’s leadership emphasized that this move reflects the company’s rapid innovation trajectory. Dr. Ellen de Brabander, Executive Vice President of Innovation and Regulatory Affairs, noted, “Over the past several years, Elanco has created a one-of-a-kind innovation powerhouse that has maximized capacity and throughput, delivering a continuous flow of differentiated products… We will continue to invest in the capacity and capabilities to bring new solutions to market that help pets live healthier, more active, longer lives and help farmers improve animal health, welfare and sustainability.”
This investment marks a major step in expanding U.S.-based animal health innovation while strengthening supply chain resilience and future product development.
Audio Reporting by Dale Sandlin for Southeast AgNet.